AU5772396A - 3,4-disubstituted-phenylsulphonamides and their therapeutic use - Google Patents

3,4-disubstituted-phenylsulphonamides and their therapeutic use

Info

Publication number
AU5772396A
AU5772396A AU57723/96A AU5772396A AU5772396A AU 5772396 A AU5772396 A AU 5772396A AU 57723/96 A AU57723/96 A AU 57723/96A AU 5772396 A AU5772396 A AU 5772396A AU 5772396 A AU5772396 A AU 5772396A
Authority
AU
Australia
Prior art keywords
phenylsulphonamides
disubstituted
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57723/96A
Inventor
Hazel Joan Dyke
John Montana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chirotech Technology Ltd
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9510163.0A external-priority patent/GB9510163D0/en
Priority claimed from GBGB9523677.4A external-priority patent/GB9523677D0/en
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of AU5772396A publication Critical patent/AU5772396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
AU57723/96A 1995-05-19 1996-05-20 3,4-disubstituted-phenylsulphonamides and their therapeutic use Abandoned AU5772396A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9510163 1995-05-19
GBGB9510163.0A GB9510163D0 (en) 1995-05-19 1995-05-19 Novel compounds
GBGB9523677.4A GB9523677D0 (en) 1995-11-20 1995-11-20 Novel compounds
GB9523677 1995-11-20
PCT/GB1996/001205 WO1996036596A1 (en) 1995-05-19 1996-05-20 3,4-disubstituted-phenylsulphonamides and their therapeutic use

Publications (1)

Publication Number Publication Date
AU5772396A true AU5772396A (en) 1996-11-29

Family

ID=26307054

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57723/96A Abandoned AU5772396A (en) 1995-05-19 1996-05-20 3,4-disubstituted-phenylsulphonamides and their therapeutic use

Country Status (2)

Country Link
AU (1) AU5772396A (en)
WO (1) WO1996036596A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2162467C2 (en) * 1996-05-20 2001-01-27 Дарвин Дискавери Лимитед Benzofuran carboxamides and pharmaceutical composition containing thereof
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6069151A (en) * 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
US6162830A (en) * 1997-11-25 2000-12-19 Warner-Lambert Company Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
JP2001026506A (en) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd Sulfonamide derivative
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
ATE320800T1 (en) 1999-08-21 2006-04-15 Altana Pharma Ag SYNERGISTIC COMBINATION OF ROFLUMILAST AND SALMETEROL
AU781365B2 (en) * 1999-12-21 2005-05-19 Icagen, Inc. Potassium channel inhibitors
AU2001237309A1 (en) 2000-01-18 2001-07-31 Novartis Ag Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
US6566380B2 (en) 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
AU2003219913A1 (en) * 2002-02-27 2003-09-09 Teva Pharmaceutical Industries, Ltd. Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20050014786A1 (en) 2003-07-11 2005-01-20 Chongqing Sun Tetrahydroquinoline derivatives as cannabinoid receptor modulators
JP5312743B2 (en) * 2006-02-01 2013-10-09 富士フイルム株式会社 Oxime compound and photosensitive composition containing the same
JP2008249857A (en) * 2007-03-29 2008-10-16 Fujifilm Corp Photosensitive resin composition, color filter and its production method, and liquid crystal display element
KR20090104877A (en) * 2007-01-23 2009-10-06 후지필름 가부시키가이샤 Oxime compound, photosensitive composition, color filter, method for production of the color filter, and liquid crystal display element
US8252829B2 (en) 2009-06-05 2012-08-28 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
CN105111095A (en) * 2015-08-26 2015-12-02 吴玲 Method for preparing S-5,6-dimethoxy-1-aminoindane
CN105175272A (en) * 2015-08-31 2015-12-23 吴玲 Method for preparing R-5-bromo-1-aminoindane

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306846A3 (en) * 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Synergistic combination comprising a phosphodiesterase inhibitor and a thromboxane-a2 antagonist, and its use or preparation
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
IL106517A0 (en) * 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group

Also Published As

Publication number Publication date
WO1996036596A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772396A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
HRP960365B1 (en) New medicaments and the use thereof
AU6282196A (en) Therapeutic glove
AU1372897A (en) 2-amino-heterocycles and therapeutic uses therefor
AU6124296A (en) Novel dolastatin derivatives, their preparation and use
AU4266596A (en) Composition and use
AU4329396A (en) Use of 3,4-diphenylchromans
AU7095296A (en) Phosphorylamides, their preparation and use
GR3031710T3 (en) Oxazolidinone derivatives, their preparation and therapeutical use
AU3634595A (en) Bis-oxazolidines and their use
HUP9600730A1 (en) 1,4-tetrazolinone-derivatives and use thereof as herbicides
AU7529796A (en) S-nitroso-hemoglobin and therapeutic uses thereof
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AU7139996A (en) Mercaptoamide derivatives and their therapeutic use
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
AU5188296A (en) Carbopeptoids and carbonucleotoids
AU2154695A (en) Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
AU5697996A (en) Peptidyl compounds and their therapeutic use
AU3982695A (en) Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines and their use as medicaments
AU3118395A (en) Oligonucleotides and their use
AU5272296A (en) Benzopyranopyrrole compounds, their preparation and use
AU5975094A (en) 1,2,4-triazinone derivatives and their use in therapy
AU1289695A (en) Human stanniocalcin-alpha